D033: Immunometabolic interplay in pediatric chronic myeloid leukemia: from immunosuppression to synthetic lethality
FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.07.2020
End date : 31.12.2022
Extension date: 30.06.2023
Project details
Scientific Abstract
Despite the improvement through tyrosine kinase inhibitors (TKIs), treatment resistance, relapse and therapy-induced side effects are central problems of CML therapy. Our interdisciplinary project addresses the question whether and how TKIs alter CML cell metabolism and induce synthetic lethality in combination with compounds specifically targeting metabolic pathways. Our approach could help to improve efficacy and reduce side effects of CML treatment in pediatric and adult patients alike.
Involved:
Contributing FAU Organisations:
Professur für Hämatologie/Onkologie mit dem Schwerpunkt Tumorimmunologie
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Medizinische Fakultät
